Liquid biopsy study aims to improve pancreatic cancer treatment
NCT ID NCT04241367
First seen May 01, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study looked for biological markers in the blood (liquid biopsy) that could help predict how well pancreatic cancer patients respond to treatment. It involved 420 people with pancreatic cancer. The goal was to find better ways to personalize treatment by analyzing tumor DNA circulating in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,
Goyang-si, Gyeonggi-do, 410-769, South Korea
Conditions
Explore the condition pages connected to this study.